Accepted for Publication: May 24, 2022.
Published Online: June 13, 2022. doi:10.1001/jama.2022.9745
Corresponding Author: Jefferson M. Jones, MD, MPH, Centers for Disease Control and Prevention, MS V18-4, 1600 Clifton Rd NE, Atlanta, GA 30329-4027 (ioe8@cdc.gov).
Author Contributions: Dr Opsomer had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Jones, Stone, Stramer, Busch.
Acquisition, analysis, or interpretation of data: Jones, Opsomer, Stone, Benoit, Ferg, Stramer, Busch.
Drafting of the manuscript: Jones, Opsomer, Stramer, Busch.
Critical revision of the manuscript for important intellectual content: Jones, Stone, Benoit, Ferg, Stramer, Busch.
Statistical analysis: Opsomer, Ferg, Busch.
Obtained funding: Jones, Stone, Busch.
Administrative, technical, or material support: Jones, Stone, Benoit, Stramer, Busch.
Supervision: Jones, Stone, Stramer, Busch.
Conflict of Interest Disclosures: Dr Stramer reported receiving a contract from the Centers for Disease Control and Prevention (CDC) via Vitalant Research Institute outside the submitted work. Dr Busch reported being an employee of Vitalant Research Institute and serving on the medical advisory board for Creative Testing Systems; Vitalant Research Institute receives research funds and reagents for studies from Ortho and Roche and Dr Busch has presented on behalf of both companies at meetings, with travel support, but does not receive personal compensation from these or other SARS-CoV-2 test-manufacturing companies. No other disclosures were reported.
Funding/Support: This study was funded by the CDC.
Role of the Funder/Sponsor: CDC employees contributed to the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The CDC did not have the right to veto publication or to control the decision regarding to which journal the study was submitted.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.
Additional Contributions: We thank Dane Freeman, PhD, Georgia Tech Research Institute, for graphic assistance; he was compensated for his role in the study. We thank members from Vitalant Research Institute, Westat, American Red Cross, Georgia Tech Research Institute, all participating blood collection organizations, and all testing laboratories for their assistance on this project (see Supplement for organization and names of the National Blood Donor Seroprevalence Study team). Finally, we thank all blood donors who contributed to this study.
4.Ferdinands
JM , Rao
S , Dixon
BE ,
et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance—VISION Network, 10 states, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep. 2022;71(7):255-263. doi:
10.15585/mmwr.mm7107e2PubMedGoogle ScholarCrossref